Patents by Inventor Matthew Fowler
Matthew Fowler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11964070Abstract: A disinfectant and sanitizer canister system is disclosed. The system may include a pre-pressurized canister being pre-filled with one or more liquid cleaners and one or more propellants. The system may further include a valve sub-system including a dispensing valve and a valve control mechanism. The control mechanism may be configured to regulate the pressure of the pre-pressurized canister to cause the pre-pressurized canister to release the one or more liquid cleaners. The system may further include a dispensing sub-system configured to fluidically couple the pre-pressurized canister to the valve sub-system. The dispensing sub-system may include a dispensing member configured to dispense the one or more liquid cleaners contained within the pressurized canister. The system may further include a metering device, the metering device configured to provide a predetermined amount of pressure to dispense a predetermined metered dose of the one or more liquid cleaners.Type: GrantFiled: June 9, 2021Date of Patent: April 23, 2024Assignee: QUIN GLOBAL US, INC.Inventors: Matthew Petersen, Carl Fowler, Jayden Earl
-
Patent number: 11931663Abstract: An automated damping system including a damping device arranged and disposed to provide variable resistance to a load. The variable resistance provides resistance values corresponding to a displacement position of the damping device. The system includes a damping profile generator that calculates a damping profile and a sensor is arranged and disposed to measure one or more damping affecting properties. The sensor provides the one or more damping affecting properties to the damping profile generator. The damping profile provides the variable resistance based upon the one or more damping affecting properties of the load.Type: GrantFiled: July 30, 2021Date of Patent: March 19, 2024Assignee: TAIT TOWERS MANUFACTURING, LLCInventors: Matthew Steven Bettinger, Nicholas James Bonsell, Andrew Phillips Mudie, Andrew John Penney, James Fowler Shumway, Jr., McLane Walker Snow
-
Publication number: 20240086851Abstract: A method for distributing an interactive digital event program to a plurality of user devices comprising: receiving a request for an interactive digital event program from a first user device, the request received in response to scanning a first tag having a machine-readable code with the first user device; determining that the first tag belongs to a first group of tags to which a first version of the interactive digital event program is to be distributed; providing the first user device with the first version of the interactive digital event program, the first version of the interactive digital event program to include at least one dynamic content element that is capable of being updated while an event is in progress; and updating the at least one dynamic content element in the first version of the interactive digital event program in response to a predefined trigger.Type: ApplicationFiled: October 5, 2023Publication date: March 14, 2024Inventors: Cameron Fowler, Matthew Sullivan
-
Publication number: 20240076270Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.Type: ApplicationFiled: January 26, 2023Publication date: March 7, 2024Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
-
Patent number: 11597701Abstract: Synthetic ?v?6 integrin ligands of Formula I having serum stability and affinity for integrin ?v?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin ?v?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include ?v?6 integrin ligands and methods of use are also described.Type: GrantFiled: October 31, 2018Date of Patent: March 7, 2023Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
-
Publication number: 20220402947Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.Type: ApplicationFiled: February 15, 2019Publication date: December 22, 2022Inventors: Zhen Li, Erich Altenhofer, Jeffrey Carlson, Matthew Fowler-Watters, Bo Chen
-
Publication number: 20220204976Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.Type: ApplicationFiled: January 8, 2020Publication date: June 30, 2022Inventors: Zhen Li, Dongxu Shu, Anthony Nicholas, Rui Zhu, Jeffrey Carlson, So Wong, Xiaokai Li, Erich Altenhofer, Matthew Fowler-Watters, Bo Chen
-
Publication number: 20220024975Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: ApplicationFiled: October 14, 2021Publication date: January 27, 2022Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Patent number: 11180529Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: GrantFiled: April 30, 2019Date of Patent: November 23, 2021Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Publication number: 20210093725Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.Type: ApplicationFiled: April 26, 2019Publication date: April 1, 2021Inventors: Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
-
Publication number: 20210069337Abstract: Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ?v?3 integrin and/or ?v?5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ?v?3, integrin ?v?5, or both integrin ?v?3 and integrin ?v?5. Compositions that include integrin targeting ligands and methods of use are also described.Type: ApplicationFiled: October 23, 2020Publication date: March 11, 2021Inventors: Zhen Li, Jeffrey Carlson, Anthony Nicholas, Xiaokai Li, Dongxu Shu, Matthew Fowler-Watters
-
Publication number: 20200369613Abstract: Synthetic av?6 integrin ligands of Formula I having serum stability and affinity for integrin av?6, which is a receptor expressed in a variety of cell types, are described. The described ligands are useful for delivering cargo molecules, such as RNAi agents or other oligonucleotide-based compounds, to cells that express integrin av?6, and thereby facilitating the uptake of the cargo molecules into these cells. Compositions that include avB6 integrin ligands and methods of use are also described.Type: ApplicationFiled: October 31, 2018Publication date: November 26, 2020Inventors: Zhen Li, Xiaokai Li, Erik W. Bush, Rui Zhu, Dongxu Shu, Jonathan Benson, Patrick Shao, Matthew Fowler-Watters
-
Publication number: 20190248832Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.Type: ApplicationFiled: April 30, 2019Publication date: August 15, 2019Inventors: Aaron Almeida, Zhen Li, Erik W. Bush, Tao Pei, Agnieszka Glebocka, Anthony Nicholas, Jeffrey Carlson, Matthew Fowler-Watters
-
Patent number: 9922075Abstract: Transactional data accesses are performed in a data storage system, where the data storage system is configured to store a plurality of data objects identified by respective key values. A request is received to modify the value of a particular data object. The request specifies a modified object value and a key value identifying the data object to be modified. In response to the request, a transactional data object is created, the transactional data object specifying a transaction identifier, the original object value and the modified object value. The transactional data object is stored in the data storage system, and associated with the key value.Type: GrantFiled: September 18, 2012Date of Patent: March 20, 2018Assignee: New Technology/Enterprise Ltd.Inventor: Matthew Fowler
-
Publication number: 20140330767Abstract: Transactional data accesses are performed in a data storage system, where the data storage system is configured to store a plurality of data objects identified by respective key values. A request is received to modify the value of a particular data object. The request specifies a modified object value and a key value identifying the data object to be modified. In response to the request, a transactional data object is created, the transactional data object specifying a transaction identifier, the original object value and the modified object value. The transactional data object is stored in the data storage system, and associated with the key value.Type: ApplicationFiled: September 18, 2012Publication date: November 6, 2014Inventor: Matthew Fowler
-
Patent number: 8838534Abstract: A system and method for processing a distributed transaction for an application are disclosed. Conventionally transactions on critical data (e.g. financial information) are processed using a database architecture whereby a persistent database (typically a redundant disk array) comprises the master record. In cases where large amounts of data need to be accessed but absolute data integrity is less critical, for example search engines, processing is conducted on live in-memory data without all the data being backed up, which can be much faster but data can be lost when processors fail. There have been attempts to use data grid architectures with some backup to persistent stores for more important data but these have either introduced disk access bottlenecks or required manual intervention in the event of failure.Type: GrantFiled: March 5, 2010Date of Patent: September 16, 2014Assignee: Cloudtran, Inc.Inventor: Matthew Fowler
-
Publication number: 20110041006Abstract: A system and method for processing a distributed transaction for an application are disclosed. Conventionally transactions on critical data (e.g. financial information) are processed using a database architecture whereby a persistent database (typically a redundant disk array) comprises the master record. In cases where large amounts of data need to be accessed but absolute data integrity is less critical, for example search engines, processing is conducted on live in-memory data without all the data being backed up, which can be much faster but data can be lost when processors fail. There have been attempts to use data grid architectures with some backup to persistent stores for more important data but these have either introduced disk access bottlenecks or required manual intervention in the event of failure.Type: ApplicationFiled: March 5, 2010Publication date: February 17, 2011Applicant: New Technology/enterprise LimitedInventor: Matthew Fowler
-
Publication number: 20080082959Abstract: Aspects of a model development and code generation system and method are described. One aspect of the system generates program code for implementing a software system specified by specification data, which may represent a model of a system designed by a user. The system includes an input component adapted to receive the specification data, a processing component adapted to generate further specification data in dependence on the received specification data and a code generator adapted to generate the program code from the specification data and the further specification data. The code generator may use templates and controls to generate program code and the further specification data may be generated based on a meta-model developed by the user.Type: ApplicationFiled: April 20, 2007Publication date: April 3, 2008Applicant: New Technology/enterprise LimitedInventor: Matthew Fowler
-
Patent number: 4780667Abstract: A discriminator having a power divider that divides a signal under test into a signal channel component and a reference channel component. A tunable delay line, such as a magnetostatic wave delay line, inserts a delay into the reference channel. A multielement input transducer selects a narrow band of spin wave wavelengths that are activated, thereby producing frequency discrimination. A phase detector is responsive to both channels to produce an output signal to a spectrum analyzer. A feedback loop, responsive to the output signal of the phase detector automatically places these two components into a quadrature relationship. The discriminator is automatically calibrated by tuning the delay line to values away from the quadrature condition in order to determine the discriminator consant.Type: GrantFiled: June 25, 1985Date of Patent: October 25, 1988Assignee: Hewlett-Packard CompanyInventors: Elias Reese, Jr., Waguih Ishak, Matthew A. Fowler, Thomas A. Jerse